GILEAD SCIENCES, INC. (GILD) Factsheet
Earnings-call transcript: covered (issuer-published) · IR deck: cataloged — watch a real agent read these end-to-end →
GILEAD SCIENCES, INC. (GILD) Stock Analysis
Analysis from 10-Q filed 2026-08-06. Data as of Q2 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC -6.9%. FCF margin 42.5%. D/E 2.2x. Source: 10-Q filed 2026-08-06.
| Metric | Value | Context |
|---|---|---|
| ROIC | -6.9% | Below expectations |
| FCF Margin | 42.5% | Strong cash generation |
| Debt/Equity | 2.2x | Elevated debt |
ROIC -6.9% — Top 50% of sector peers. FCF margin 42.5% — Top 5%.
Explore GILEAD SCIENCES, INC.: Earnings History | Filings
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for GILD: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: GILEAD SCIENCES, INC. earns -6.9% ROIC, Top 50% in Healthcare
ROIC TTM -6.9%, sector median -7.5%, Top 50%. DuPont: NOPAT margin -10.2% × asset turnover 0.5x. Gross margin 79.6%. Operating margin -8.2%. Source: 10-Q filed 2026-08-06.
| Metric | GILD | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | -6.9% | Red flag | Above sector median of -7.5% |
| Return on Equity (ROE) | -15.5% | Red flag | Moderate equity returns |
| Gross Margin | 79.6% | Excellent | Strong pricing power |
| Operating Margin | -8.2% | Warning | Moderate operational efficiency |
Cash Flow: GILEAD SCIENCES, INC. generates $12.9B FCF at 42.5% margin, positive NaN/8 quarters
FCF TTM $12.9B. FCF margin 42.5%, Top 5%. OCF/Net income -4.2x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2026-08-06.
| Metric | GILD | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 42.5% | Excellent | Excellent cash conversion |
| Free Cash Flow (TTM) | $12.9B | Good | Positive cash generation |
| OCF/Net Income | -4.2x | Warning | Potential accrual concerns |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: GILEAD SCIENCES, INC. at 2.2x leverage, -2.5x interest coverage
Debt/Equity 2.2x. Total debt $26.2B, cash & investments $3.2B. Interest coverage -2.5x. Source: 10-Q filed 2026-08-06.
| Metric | GILD | Rating | Context |
|---|---|---|---|
| Debt to Equity | 2.2x | Warning | Elevated leverage |
| Net Cash Position | $-23.1B | Warning | Net debt position |
| Interest Coverage | -2.5x | Warning | Monitor debt obligations |
Valuation: GILEAD SCIENCES, INC. trades at -58.0x earnings
P/E -58.0x. EV/Sales 6.9x. FCF yield 6.9%. Dividend yield 2.2%. Source: 10-Q filed 2026-08-06.
| Metric | GILD | Rating | Context |
|---|---|---|---|
| P/E Ratio | -58.0x | Red flag | Reasonable valuation |
| EV/Sales | 6.9x | Adequate | Growth premium priced in |
| FCF Yield | 6.9% | Good | Attractive cash return |
| Dividend Yield | 2.2% | Adequate | Growth focus over income |
Capital Allocation: GILEAD SCIENCES, INC. returns 2.9% shareholder yield, reducing shares 0.1% YoY
Total shareholder yield 2.9% (div 2.2% + buyback 0.8%). Share count -0.1% YoY. Capital returned $5.5B TTM. Source: 10-Q filed 2026-08-06.
| Metric | GILD | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 2.9% | Adequate | Dividend + buyback yield combined |
| Buyback Yield | 0.8% | Adequate | Minimal buyback activity |
| Share Count Change (YoY) | -0.1% | Adequate | Net share reduction (accretive) |
| Total Capital Returned (TTM) | $5.5B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | -6.9% | Top 50% | - |
| Free Cash Flow Margin | 42.5% | Top 5% | - |
| Gross Margin | 79.6% | Top 25% | 1.2x above |
| Operating Margin | -8.2% | Bottom 50% | - |
| Return on Equity (ROE) | -15.5% | Top 50% | - |
Financial Scorecard
| Metric | GILD | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | -6.9% | Red flag | Top 50% of sector (median: -7.5%) |
| Free Cash Flow Margin | 42.5% | Excellent | Top 5% of sector (median: 0.0%) |
| Gross Margin | 79.6% | Excellent | Top 25% of sector (median: 63.8%) |
| Debt to Equity Ratio | 221.9% | Warning | High financial leverage |
| Free Cash Flow Yield | 6.9% | Good | Solid cash yield |
Frequently Asked Questions
Q: What is GILEAD SCIENCES, INC.'s Return on Invested Capital (ROIC)?
GILEAD SCIENCES, INC. (GILD) has a trailing twelve-month Return on Invested Capital (ROIC) of -6.9%. The 8-quarter median ROIC is 17.5% with a declining trend. Sector median -7.5%. Source: 10-Q filed 2026-08-06.
Q: What is GILEAD SCIENCES, INC.'s Free Cash Flow Margin?
GILEAD SCIENCES, INC. (GILD) has a free cash flow margin of 42.5%, generating $12.9 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2026-08-06.
Q: What is GILEAD SCIENCES, INC.'s P/E ratio and how does it compare to peers?
GILEAD SCIENCES, INC. (GILD) trades at a P/E ratio of -58.0x, which is above the sector median of N/A. EV/Sales 6.9x. FCF yield 6.9%. Source: 10-Q filed 2026-08-06.
Q: Does GILEAD SCIENCES, INC. pay a dividend?
GILEAD SCIENCES, INC. (GILD) currently pays a dividend yield of 2.2%. Total shareholder yield (dividend + buybacks) 2.9%. Source: 10-Q filed 2026-08-06.
Q: How much debt does GILEAD SCIENCES, INC. have?
GILEAD SCIENCES, INC. (GILD) has a debt-to-equity ratio of 2.2x with total debt of $26.2 billion. Interest coverage -2.5x. Net debt $23.1 billion. Source: 10-Q filed 2026-08-06.
Q: What is GILEAD SCIENCES, INC.'s revenue and earnings growth?
GILEAD SCIENCES, INC. (GILD) grew revenue by 5.5% year-over-year. Source: 10-Q filed 2026-08-06.
Q: Is GILEAD SCIENCES, INC. buying back stock?
GILEAD SCIENCES, INC. (GILD) repurchased $1.4 billion of stock over the trailing twelve months. This represents a buyback yield of 0.8%. Share count -0.1% YoY. Source: 10-Q filed 2026-08-06.
Q: How does GILEAD SCIENCES, INC. compare to competitors in Healthcare?
Compared to other companies in Healthcare, GILEAD SCIENCES, INC. (GILD) shows: ROIC -6.9%, sector median -7.5% (Top 50%). FCF margin 42.5%, sector median 0.0% (Top 5%). Gross margin 79.6%, 15.8pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with GILEAD SCIENCES, INC.?
Quantitative warning flags for GILEAD SCIENCES, INC. (GILD): 1) ROIC declining -64.9% over 8 quarters; 2) debt/equity 2.2x (above 1.5x threshold); 3) interest coverage -2.5x (below 5x). Source: 10-Q filed 2026-08-06.
Data Source: Data sourced from 10-Q filed 2026-08-06. TTM metrics as of Q2 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.